Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia
Recently, the identification of minimal residual disease (MRD) that persists after chemotherapy has emerged as the most powerful tool in determining the prognosis of patients with acute lymphoblastic leukemia (ALL). Multiple methods to detect MRD exist, each with its own benefits and drawback. Multi...
Gespeichert in:
| Veröffentlicht in: | Asian Pacific Journal of Cancer Prevention 2023-10, Vol.24 (10), p.3577-3584 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3584 |
|---|---|
| container_issue | 10 |
| container_start_page | 3577 |
| container_title | Asian Pacific Journal of Cancer Prevention |
| container_volume | 24 |
| creator | Algamal, Reem Ahmed Abu Samra, Nashwa Khairt Ellashery, Rasha Abd-elmalk Abd-EL-Hameed, Suzy Abd Elamabood Shahin, Doaa Abdelhalim |
| description | Recently, the identification of minimal residual disease (MRD) that persists after chemotherapy has emerged as the most powerful tool in determining the prognosis of patients with acute lymphoblastic leukemia (ALL). Multiple methods to detect MRD exist, each with its own benefits and drawback. Multiparameter flow cytometry and quantitative polymerase chain reaction are the most commonly used methods of MRD detection in clinical practice.
to evaluate the impact of minimal residual disease detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
The study conducted on 93 patients with recently diagnosed acute lymphoblastic leukemia. MRD detection was evaluated during follow up of patient (at End of induction EOI and End of consolidation EOC by next generation flow cytometry.
Out of 93 patients, 28 (30%) had positive MRD at EOI. Age, BCR-ABL, risk assessment, and relapse had a substantial impact on MRD at EOI (P |
| doi_str_mv | 10.31557/APJCP.2023.24.10.3577 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10770696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37898866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2777-427b2ab8469d6fa696930d4ef76434ebae744a86a19487706286d54a6e46d7043</originalsourceid><addsrcrecordid>eNpVkVtOwzAQRS0EouWxhcobaHEcx06-UNXSAipQIZD4s5xk0hryUuxQsguWjFuggi-P78w9Y_kiNPDIyPeCQFyMl7eT5YgS6o8oG23lQIgD1KdM8KHg9OXwT91DJ8a8EsKCUATHqOeLMApDzvvo86aoVWJxleE7XepC5fgRjE5bV0y1AWUAT8FCYnVV4rjD9_Bh8RxKaNROmuXVBk86WxVgmw475aG1ibttkVerrrZalXjphqG0Bm-0XeNx0lrAi66o11WcK2N1ghfQvkGh1Rk6ylRu4PznPEXPs6unyfVw8TC_mYwXw4QKIYaMipiqOGQ8SnmmeMQjn6QMMsGZzyBWIBhTIVdexEIhCKchTwOmODCeCsL8U3T5za3buIA0ca9rVC7rxv1B08lKafm_U-q1XFXv0iNbXMQdgX8TkqYypoFsb_aI3IUkdyHJbUiSsp3sQnLGwd_Ve9tvKv4X8fGRhg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Algamal, Reem Ahmed ; Abu Samra, Nashwa Khairt ; Ellashery, Rasha Abd-elmalk ; Abd-EL-Hameed, Suzy Abd Elamabood ; Shahin, Doaa Abdelhalim</creator><creatorcontrib>Algamal, Reem Ahmed ; Abu Samra, Nashwa Khairt ; Ellashery, Rasha Abd-elmalk ; Abd-EL-Hameed, Suzy Abd Elamabood ; Shahin, Doaa Abdelhalim</creatorcontrib><description>Recently, the identification of minimal residual disease (MRD) that persists after chemotherapy has emerged as the most powerful tool in determining the prognosis of patients with acute lymphoblastic leukemia (ALL). Multiple methods to detect MRD exist, each with its own benefits and drawback. Multiparameter flow cytometry and quantitative polymerase chain reaction are the most commonly used methods of MRD detection in clinical practice.
to evaluate the impact of minimal residual disease detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
The study conducted on 93 patients with recently diagnosed acute lymphoblastic leukemia. MRD detection was evaluated during follow up of patient (at End of induction EOI and End of consolidation EOC by next generation flow cytometry.
Out of 93 patients, 28 (30%) had positive MRD at EOI. Age, BCR-ABL, risk assessment, and relapse had a substantial impact on MRD at EOI (P <0.005). Fourteen patients (17.9%) at EOC were MRD positive; age, hemoglobin, blast count at diagnosis, BCR-ABL, risk stratification, relapse and overall survival showed significant association.
Positive MRD was a major risk factor for predicting poor survival and relapse at both EOI and EOC by cox regression analysis.</description><identifier>ISSN: 2476-762X</identifier><identifier>ISSN: 1513-7368</identifier><identifier>EISSN: 2476-762X</identifier><identifier>DOI: 10.31557/APJCP.2023.24.10.3577</identifier><identifier>PMID: 37898866</identifier><language>eng</language><publisher>Thailand: West Asia Organization for Cancer Prevention</publisher><subject>Egypt - epidemiology ; Flow Cytometry - methods ; Humans ; Neoplasm, Residual - diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Prognosis ; Recurrence</subject><ispartof>Asian Pacific Journal of Cancer Prevention, 2023-10, Vol.24 (10), p.3577-3584</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-4900-5772</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770696/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770696/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37898866$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Algamal, Reem Ahmed</creatorcontrib><creatorcontrib>Abu Samra, Nashwa Khairt</creatorcontrib><creatorcontrib>Ellashery, Rasha Abd-elmalk</creatorcontrib><creatorcontrib>Abd-EL-Hameed, Suzy Abd Elamabood</creatorcontrib><creatorcontrib>Shahin, Doaa Abdelhalim</creatorcontrib><title>Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia</title><title>Asian Pacific Journal of Cancer Prevention</title><addtitle>Asian Pac J Cancer Prev</addtitle><description>Recently, the identification of minimal residual disease (MRD) that persists after chemotherapy has emerged as the most powerful tool in determining the prognosis of patients with acute lymphoblastic leukemia (ALL). Multiple methods to detect MRD exist, each with its own benefits and drawback. Multiparameter flow cytometry and quantitative polymerase chain reaction are the most commonly used methods of MRD detection in clinical practice.
to evaluate the impact of minimal residual disease detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
The study conducted on 93 patients with recently diagnosed acute lymphoblastic leukemia. MRD detection was evaluated during follow up of patient (at End of induction EOI and End of consolidation EOC by next generation flow cytometry.
Out of 93 patients, 28 (30%) had positive MRD at EOI. Age, BCR-ABL, risk assessment, and relapse had a substantial impact on MRD at EOI (P <0.005). Fourteen patients (17.9%) at EOC were MRD positive; age, hemoglobin, blast count at diagnosis, BCR-ABL, risk stratification, relapse and overall survival showed significant association.
Positive MRD was a major risk factor for predicting poor survival and relapse at both EOI and EOC by cox regression analysis.</description><subject>Egypt - epidemiology</subject><subject>Flow Cytometry - methods</subject><subject>Humans</subject><subject>Neoplasm, Residual - diagnosis</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Prognosis</subject><subject>Recurrence</subject><issn>2476-762X</issn><issn>1513-7368</issn><issn>2476-762X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkVtOwzAQRS0EouWxhcobaHEcx06-UNXSAipQIZD4s5xk0hryUuxQsguWjFuggi-P78w9Y_kiNPDIyPeCQFyMl7eT5YgS6o8oG23lQIgD1KdM8KHg9OXwT91DJ8a8EsKCUATHqOeLMApDzvvo86aoVWJxleE7XepC5fgRjE5bV0y1AWUAT8FCYnVV4rjD9_Bh8RxKaNROmuXVBk86WxVgmw475aG1ibttkVerrrZalXjphqG0Bm-0XeNx0lrAi66o11WcK2N1ghfQvkGh1Rk6ylRu4PznPEXPs6unyfVw8TC_mYwXw4QKIYaMipiqOGQ8SnmmeMQjn6QMMsGZzyBWIBhTIVdexEIhCKchTwOmODCeCsL8U3T5za3buIA0ca9rVC7rxv1B08lKafm_U-q1XFXv0iNbXMQdgX8TkqYypoFsb_aI3IUkdyHJbUiSsp3sQnLGwd_Ve9tvKv4X8fGRhg</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Algamal, Reem Ahmed</creator><creator>Abu Samra, Nashwa Khairt</creator><creator>Ellashery, Rasha Abd-elmalk</creator><creator>Abd-EL-Hameed, Suzy Abd Elamabood</creator><creator>Shahin, Doaa Abdelhalim</creator><general>West Asia Organization for Cancer Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4900-5772</orcidid></search><sort><creationdate>20231001</creationdate><title>Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia</title><author>Algamal, Reem Ahmed ; Abu Samra, Nashwa Khairt ; Ellashery, Rasha Abd-elmalk ; Abd-EL-Hameed, Suzy Abd Elamabood ; Shahin, Doaa Abdelhalim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2777-427b2ab8469d6fa696930d4ef76434ebae744a86a19487706286d54a6e46d7043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Egypt - epidemiology</topic><topic>Flow Cytometry - methods</topic><topic>Humans</topic><topic>Neoplasm, Residual - diagnosis</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Prognosis</topic><topic>Recurrence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Algamal, Reem Ahmed</creatorcontrib><creatorcontrib>Abu Samra, Nashwa Khairt</creatorcontrib><creatorcontrib>Ellashery, Rasha Abd-elmalk</creatorcontrib><creatorcontrib>Abd-EL-Hameed, Suzy Abd Elamabood</creatorcontrib><creatorcontrib>Shahin, Doaa Abdelhalim</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Algamal, Reem Ahmed</au><au>Abu Samra, Nashwa Khairt</au><au>Ellashery, Rasha Abd-elmalk</au><au>Abd-EL-Hameed, Suzy Abd Elamabood</au><au>Shahin, Doaa Abdelhalim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia</atitle><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle><addtitle>Asian Pac J Cancer Prev</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>24</volume><issue>10</issue><spage>3577</spage><epage>3584</epage><pages>3577-3584</pages><issn>2476-762X</issn><issn>1513-7368</issn><eissn>2476-762X</eissn><abstract>Recently, the identification of minimal residual disease (MRD) that persists after chemotherapy has emerged as the most powerful tool in determining the prognosis of patients with acute lymphoblastic leukemia (ALL). Multiple methods to detect MRD exist, each with its own benefits and drawback. Multiparameter flow cytometry and quantitative polymerase chain reaction are the most commonly used methods of MRD detection in clinical practice.
to evaluate the impact of minimal residual disease detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
The study conducted on 93 patients with recently diagnosed acute lymphoblastic leukemia. MRD detection was evaluated during follow up of patient (at End of induction EOI and End of consolidation EOC by next generation flow cytometry.
Out of 93 patients, 28 (30%) had positive MRD at EOI. Age, BCR-ABL, risk assessment, and relapse had a substantial impact on MRD at EOI (P <0.005). Fourteen patients (17.9%) at EOC were MRD positive; age, hemoglobin, blast count at diagnosis, BCR-ABL, risk stratification, relapse and overall survival showed significant association.
Positive MRD was a major risk factor for predicting poor survival and relapse at both EOI and EOC by cox regression analysis.</abstract><cop>Thailand</cop><pub>West Asia Organization for Cancer Prevention</pub><pmid>37898866</pmid><doi>10.31557/APJCP.2023.24.10.3577</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-4900-5772</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2476-762X |
| ispartof | Asian Pacific Journal of Cancer Prevention, 2023-10, Vol.24 (10), p.3577-3584 |
| issn | 2476-762X 1513-7368 2476-762X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10770696 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals |
| subjects | Egypt - epidemiology Flow Cytometry - methods Humans Neoplasm, Residual - diagnosis Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Prognosis Recurrence |
| title | Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T06%3A29%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Minimal%20Residual%20Disease%20Detection%20by%20Next%20Generation%20Flow%20Cytometry%20on%20Outcome%20of%20Egyptian%20Patients%20with%20Acute%20Lymphoblastic%20Leukemia&rft.jtitle=Asian%20Pacific%20Journal%20of%20Cancer%20Prevention&rft.au=Algamal,%20Reem%20Ahmed&rft.date=2023-10-01&rft.volume=24&rft.issue=10&rft.spage=3577&rft.epage=3584&rft.pages=3577-3584&rft.issn=2476-762X&rft.eissn=2476-762X&rft_id=info:doi/10.31557/APJCP.2023.24.10.3577&rft_dat=%3Cpubmed_cross%3E37898866%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37898866&rfr_iscdi=true |